November 3, 2025—Endovascular Engineering, Inc. (E2) announced positive results from the pivotal cohort of the ENGULF investigational device exemption (IDE) study evaluating the Hēlo thrombectomy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback